Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial

[1]  H. Qureshi,et al.  EPIDEMIOLOGY OF CHALLENGING BEHAVIOUR , 2010 .

[2]  M. Crawford,et al.  Modified Overt Aggression Scale (MOAS) for People with Intellectual Disability and Aggressive Challenging Behaviour: A Reliability Study , 2007 .

[3]  M. Beneke,et al.  Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. , 2007, The British journal of psychiatry : the journal of mental science.

[4]  S. Cooper,et al.  Mental ill-health in adults with intellectual disabilities: prevalence and associated factors , 2007, British Journal of Psychiatry.

[5]  L. Thorpe,et al.  Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders , 2005, Psychopharmacology.

[6]  C. Adams,et al.  Rapid tranquillisation of violent or agitated patients Rapid tranquillisation of violent or agitated patients , 2004 .

[7]  L. Sandler.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[8]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[9]  R. Novaco,et al.  Cognitive-behavioural treatment of anger intensity among offenders with intellectual disabilities , 2002 .

[10]  B. Fraser,et al.  Are antipsychotic drugs the right treatment for challenging behaviour in learning disability?: The place of a randomised trial , 2001, Journal of medical ethics.

[11]  S. Einfeld.  Systematic management approach to pharmacotherapy for people with learning disabilities , 2001 .

[12]  M. Knapp.  Economic Evaluation of Mental Health Care , 2001 .

[13]  L. Duggan,et al.  Antipsychotic medication for challenging behaviour in people with learning disability. , 2004, The Cochrane database of systematic reviews.

[14]  C. Hatton,et al.  Receipt of psychotropic medication by people with intellectual disability in residential settings. , 2000, Journal of intellectual disability research : JIDR.

[15]  L. Duggan,et al.  Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials. , 2001, Journal of intellectual disability research : JIDR.

[16]  K. Xenitidis,et al.  An inpatient treatment model for adults with mild intellectual disability and challenging behaviour. , 1999, Journal of intellectual disability research : JIDR.

[17]  H. Costello,et al.  Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability. , 2002, Journal of intellectual disability research : JIDR.

[18]  S. Cooper,et al.  Prevalence and Cluster Typology of Maladaptive Behaviours in a Geographically Defined Population of Adults with Learning Disabilities , 1996, British Journal of Psychiatry.

[19]  J. Beecham.  Collecting and estimating costs , 1995 .

[20]  D. Branford.  A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. , 2008, Journal of intellectual disability research : JIDR.

[21]  P. Thiry,et al.  Risperidone as add‐on therapy in behavioural disturbances in mental retardation: a double‐blind placebo‐controlled cross‐over study , 1993, Acta psychiatrica Scandinavica.

[22]  M. Reichman,et al.  Rating aggression in the clinical setting. A retrospective adaptation of the Overt Aggression Scale: preliminary results. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[23]  O. Linaker.  Frequency of and Determinants for Psychotropic Drug Use in an Institution for the Mentally Retarded , 1990, British Journal of Psychiatry.

[24]  R. Pruchno.  The Effects of Help Patterns on the Mental Health of Spouse Caregivers , 1990, Research on aging.

[25]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[26]  J. Lund.  The prevalence of psychiatric morbidity in mentally retarded adults , 1985, Acta psychiatrica Scandinavica.

[27]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.

[28]  H. Bair,et al.  Efficacy of chlorpromazine in hyperactive mentally retarded children. , 1955, A.M.A. archives of neurology and psychiatry.